Press Releases

CRANBURY, N.J., Nov. 15, 2010 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company dedicated to the development of peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor systems, today announced results for its first quarter ended September 30, 2010. Palatin reported a net loss of […]

CRANBURY, N.J., Nov. 12, 2010 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its first quarter, fiscal year 2011 financial results on Tuesday, November 16, 2010 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November

CRANBURY, N.J., Nov. 2, 2010 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN), announced today that it has received $978,000 in grants under the Patient Protection and Affordable Care Act of 2010 (PPACA), with $847,000 available immediately and $131,000 available no later than 30 days after Palatin’s fiscal year ending June 30, 2011. The grants

CRANBURY, N.J., Oct. 1 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the 9th Annual BIO Investor Forum on Wednesday, October 6, 2010 at 8:00 AM PT.  Hosted by the Biotechnology Industry Organization (BIO), the 9th Annual BIO Investor Forum will take place October 5-6 at the Palace

CRANBURY, N.J., Sept. 27 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor systems, today announced results for its fourth quarter and fiscal year ended June 30, 2010.  All share and

CRANBURY, N.J., Sept. 24 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the realignment of its workforce and operations to reflect a strategic reassessment of its research and development activities and corporate objectives. As a result, Palatin will focus resources and efforts on clinical trials of bremelanotide for male and female sexual dysfunction

CRANBURY, N.J., Sept. 22 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its fourth quarter, fiscal year 2010 financial results on Monday, September 27, 2010 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 27,

CRANBURY, N.J., Sept. 10 /PRNewswire/ — Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the Rodman & Renshaw Annual Global Investment Conference / 12th Annual Healthcare Conference on Tuesday, September 14, 2010 at 10:50 AM ET.  The conference will take place September 12-15 at the New York Palace Hotel in

CRANBURY, N.J., Aug. 17 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels

CRANBURY, N.J., June 24 /PRNewswire-FirstCall/ — Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of patient dosing and database lock in a double-blind, placebo-controlled, multiple dose, crossover study of bremelanotide, its subcutaneously administered melanocortin agonist for treatment of erectile dysfunction (ED). Palatin expects to report top-line data in the next calendar quarter. The